Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease

Xu J, Luc JG, Phan K. Atrial fibrillation: review of current treatment strategies. J Thorac Dis. 2016;8:E886–900.

PubMed  PubMed Central  Google Scholar 

Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373–498.

PubMed  Google Scholar 

Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123:2946–53.

PubMed  PubMed Central  Google Scholar 

Seyed Ahmadi S, Svensson AM, Pivodic A, Rosengren A, Lind M. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovasc Diabetol. 2020;19:9.

PubMed  PubMed Central  Google Scholar 

Qiu H, Ji C, Liu W, et al. Chronic kidney disease increases atrial fibrillation inducibility: involvement of inflammation, atrial fibrosis, and connexins. Front Physiol. 2018;9:1726.

PubMed  PubMed Central  Google Scholar 

Bohne LJ, Johnson D, Rose RA, Wilton SB, Gillis AM. The association between diabetes mellitus and atrial fibrillation: clinical and mechanistic insights. Front Physiol. 2019;10:135.

PubMed  PubMed Central  Google Scholar 

Echouffo-Tcheugui JB, Shrader P, Thomas L, et al. Care patterns and outcomes in atrial fibrillation patients with and without diabetes: ORBIT-AF registry. J Am Coll Cardiol. 2017;70:1325–35.

PubMed  Google Scholar 

Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69:546–54.

Google Scholar 

Bakris GL, Agarwal R, Anker SD, FIDELIO-DKD Investigators, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219–29.

CAS  PubMed  Google Scholar 

Filippatos G, Bakris GL, Pitt B, FIDELIO-DKD Investigators, et al. Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J Am Coll Cardiol. 2021;78(2):142–52.

CAS  PubMed  Google Scholar 

Sridhar VS, Liu H, Cherney DZI. Finerenone—a new frontier in renin-angiotensin-aldosterone system inhibition in diabetic kidney disease. Am J Kidney Dis. 2021;78(2):309–11.

CAS  PubMed  Google Scholar 

Committee ADAPP. Chronic kidney disease and risk management: standards of medical care in diabetes—2022. Diabetes Care. 2022;45(Suppl. 1):S175–84.

Google Scholar 

Zinman B, Wanner C, Lachin JM, EMPA-REG OUTCOME Investigators, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

CAS  PubMed  Google Scholar 

Neal B, Perkovic V, Mahaffey KW, CANVAS Program Collaborative Group, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.

CAS  PubMed  Google Scholar 

Perkovic V, Jardine MJ, Neal B, CREDENCE Trial Investigators, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.

CAS  PubMed  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, DECLARE–TIMI 58 Investigators, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.

CAS  PubMed  Google Scholar 

Heerspink HJL, Stefánsson BV, Correa-Rotter R, DAPA-CKD Trial Committees and Investigators, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.

CAS  PubMed  Google Scholar 

Cannon CP, Pratley R, Dagogo-Jack S, VERTIS CV Investigators, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–35.

CAS  PubMed  Google Scholar 

Bhatt DL, Szarek M, Pitt B, SCORED Investigators, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129–39.

CAS  PubMed  Google Scholar 

Li WJ, Chen XQ, Xu LL, et al. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol. 2020;19(1):130.

PubMed  PubMed Central  Google Scholar 

Zhou Z, Jardine MJ, Li Q, CREDENCE Trial Investigators, et al. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis. Stroke. 2021;52(5):1545–56.

CAS  PubMed  PubMed Central  Google Scholar 

American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2022;45(Suppl 1):S125–43.

Google Scholar 

Moher D, Liberati A, Tetzlaf J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339: b2535.

PubMed  PubMed Central  Google Scholar 

Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84.

PubMed  Google Scholar 

Higins JPT, Green S. Cochrane handbook for systematic reviews of interventions. The Cochrane Collabo- ration and John Wiley & Sons Lid; 2008.

Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.

PubMed  Google Scholar 

Brignardello-Petersen R, Guyatt GH, Mustafa RA, et al. GRADE guidelines 33: addressing imprecision in a network meta-analysis. J Clin Epidemiol. 2021;139:49–56.

PubMed  Google Scholar 

Puhan MA, Schünemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349: g5630.

PubMed  Google Scholar 

Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. www.training.cochrane.org/handbook.

Pitt B, Filippatos G, Agarwal R, FIGARO-DKD Investigators, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–63.

CAS  PubMed  Google Scholar 

Filippatos G, Anker SD, Agarwal R, FIDELIO-DKD Investigators, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021;143(6):540–52.

CAS  PubMed  Google Scholar 

Qiu M, Zhao LM. Long-term cardiorenal efficacy of finerenone in patients with chronic kidney disease and type 2 diabetes. Ann Palliat Med. 2021;10(10):11239–41.

PubMed  Google Scholar 

Bakris GL, Agarwal R, Chan JC, Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884–94.

CAS  PubMed  Google Scholar 

Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol. 2014;13:102.

PubMed  PubMed Central  Google Scholar 

Wanner C, Inzucchi SE, Lachin JM, EMPA-REG OUTCOME Investigators, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–34.

CAS  PubMed  Google Scholar 

Wanner C, Lachin JM, Inzucchi SE, EMPA-REG OUTCOME Investigators, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137(2):119–29.

CAS  PubMed  Google Scholar 

Wanner C, Inzucchi SE, Zinman B, EMPA-REG OUTCOME Investigators, et al. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: insights from the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2020;22(12):2335–47.

CAS  PubMed  Google Scholar 

Barnett AH, Mithal A, Manassie J, EMPA-REG RENAL trial investigators, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369–84.

CAS  PubMed  Google Scholar 

Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019;140(9):739–50.

CAS  PubMed  PubMed Central  Google Scholar 

Ye N, Jardine MJ, Oshima M, et al. Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE Trial. Circulation. 2021;143(18):1735–49.

CAS  PubMed  Google Scholar 

Bakris G, Oshima M, Mahaffey KW, et al. Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 173 m2: subgroup analysis of the randomized CREDENCE Trial. Clin J Am Soc Nephrol. 2020;15(12):1705–14.

CAS  PubMed  PubMed Central  Google Scholar 

Jardine MJ, Zhou Z, Mahaffey KW, CREDENCE Study Investigators, et al. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J Am Soc Nephrol. 2020;31(5):1128–39.

CAS  PubMed  PubMed Central  Google Scholar 

Yale JF, Bakris G, Cariou B, DIA3004 Study, et al. Group efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16(10):1016–27.

CAS  PubMed  Google Scholar 

Persson F, Rossing P, Vart P, DAPA-CKD Trial Committees and Investigators, et al. Efficacy and safety of dapagliflozin by baseline glycemic status: a prespecified analysis from the DAPA-CKD trial. Diabetes Care. 2021;44(8):1894–7.

CAS  PubMed  PubMed Central  Google Scholar 

Heerspink HJL, Sjöström CD, Jongs N, DAPA-CKD Trial Committees and Investigators, et al. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur Heart J. 2021;42(13):1216–27.

CAS  PubMed  PubMed Central  Google Scholar 

Wheeler DC, Stefánsson BV, Jongs N, DAPA-CKD Trial

留言 (0)

沒有登入
gif